Longeveron (LGVN)
NASDAQ:LGVN
Want to see LGVN full AI Analyst Report?
LGVN Stock Chart & Stats
$1.10
-$0.07(-3.68%)
At close: 4:00 PM EST
$1.10
-$0.07(-3.68%)
Day’s Range― - ―
52-Week Range$0.48 - $1.80
Previous CloseN/A
Volume215.49K
Average Volume (3M)473.11K
Market Cap
$24.36M
Enterprise Value$383.36K
Total Cash (Recent Filing)$15.76M
Total Debt (Recent Filing)$748.00K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding30,148,947
10 Day Avg. Volume706,553
30 Day Avg. Volume473,105
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.57
Price to Sales (P/S)7.42
P/FCF Ratio-0.47
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.48
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$5.50Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$1.49M
Bulls Say, Bears Say
Bulls Say
Low LeverageRelatively minimal debt versus equity reduces near-term solvency risk and preserves financial optionality. For a cash‑burning clinical biotech, low leverage lowers immediate refinancing pressure and gives management flexibility to pursue partnerships or staged financing without high interest burdens.
Robust IP & Regulatory DesignationsA deep patent estate and multiple expedited FDA designations (RMAT, Fast Track, Orphan, Rare Pediatric Disease) strengthen barriers to entry and may accelerate regulatory interactions. These durable protections increase strategic licensing value and support longer-term commercialization optionality if clinical success is demonstrated.
Completed Enrollment; Defined Readout TimetableHaving a fully enrolled Phase IIb trial with a scheduled topline readout is a structural value inflection. It converts development risk into an analyzable clinical outcome, enabling clearer partnering, regulatory planning, or licensing decisions that materially affect the company's long‑term strategic options.
Bears Say
Regulatory Setback On Primary EndpointThe FDA rejection of RVEF as a primary endpoint creates persistent regulatory uncertainty and may raise the evidentiary bar. Without agreement on a pivotal endpoint, approval pathway timing and likelihood become unclear, complicating statistical plans, labeling prospects, and long‑term commercial viability even after readout.
Heavy Cash Burn; Limited RunwaySustained negative operating cash flow and a runway extending only to Q4 2026 imply recurrent financing needs. Persistent cash burn forces dilution risk or unfavorable financing terms, constrains R&D flexibility, and makes long‑term program execution dependent on capital markets or strategic partners.
Minimal Revenue And Ongoing LossesA tiny revenue base coupled with large, persistent net losses indicates the core business is not self‑funding. This structural deficit reduces internal reinvestment capacity and heightens reliance on external capital or partnerships to sustain development and commercialization over the next several quarters.
Longeveron News
LGVN FAQ
What was Longeveron’s price range in the past 12 months?
Longeveron lowest stock price was $0.47 and its highest was $1.80 in the past 12 months.
What is Longeveron’s market cap?
Longeveron’s market cap is $24.36M.
When is Longeveron’s upcoming earnings report date?
Longeveron’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were Longeveron’s earnings last quarter?
Longeveron released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.012.
Is Longeveron overvalued?
According to Wall Street analysts Longeveron’s price is currently Undervalued.
Does Longeveron pay dividends?
Longeveron does not currently pay dividends.
What is Longeveron’s EPS estimate?
Longeveron’s EPS estimate is -0.18.
How many shares outstanding does Longeveron have?
Longeveron has 30,148,947 shares outstanding.
What happened to Longeveron’s price movement after its last earnings report?
Longeveron reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -7.02%.
Which hedge fund is a major shareholder of Longeveron?
Currently, no hedge funds are holding shares in LGVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Longeveron
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful operational and strategic progress — completed enrollment for ELPIS II, new institutional investors, a strengthened IP and regulatory-designation profile, and modest improvements in expenses and net loss — alongside material challenges: a regulatory setback where the FDA rejected RVEF as a primary endpoint and no agreement on a new primary endpoint while the trial remains ongoing, objective-only efficacy expectations, limited cash runway into Q4 2026, and small absolute revenues. Management is pursuing partnerships and will seek FDA engagement immediately after topline results, but the regulatory uncertainty and near-term financing timeline temper optimism.View all LGVN earnings summariesLGVN Stock 12 Month Forecast
Average Price Target
$5.50
▲(400.00% Upside)
Technical Analysis
Ibio
―
Edesa Biotech
―
Chemomab Therapeutics
―
Processa Pharmaceuticals
―
FibroBiologics, Inc.
―
Ownership Overview
14.79% Insiders
2.19% Mutual Funds
0.98% Other Institutional Investors
80.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---